A Phase 1b Trial of M3814 (Peposertib) in Combination With Lutetium 177 Dotatate for Well-Differentiated Somatostatin Receptor-Positive Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
Latest Information Update: 13 Aug 2024
At a glance
- Drugs Peposertib (Primary) ; Lutetium-(177Lu)-oxodotreotide
- Indications Gastrointestinal cancer; Neuroendocrine tumours; Pancreatic cancer
- Focus Adverse reactions
- 12 Jun 2024 Planned End Date changed from 4 Jun 2024 to 4 Dec 2024.
- 12 Jun 2024 Planned primary completion date changed from 4 Jun 2024 to 4 Dec 2024.
- 01 Mar 2024 Status changed from recruiting to active, no longer recruiting.